August 23, 2024 07:00 AM EDT
Peer Review

Gen­mab makes two C-suite ad­di­tions as COO leaves; James Sabry leads a re­vamped sup­port­ing cast at Bio­Marin

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ There are sub­stan­tial lead­er­ship changes at Gen­mab, start­ing with the de­par­ture of COO An­tho­ny Manci­ni. Peer Re­view

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times